NasdaqCM:CPRXBiotechs
Catalyst Pharmaceuticals (CPRX) Could Be 60% Undervalued As Merger Approval Reshapes The Board
Board changes linked to approved merger
Catalyst Pharmaceuticals (CPRX) has moved a planned merger forward after stockholders approved a Merger Agreement at a special meeting, with all current directors indicating their intention to resign once the transaction becomes effective.
See our latest analysis for Catalyst Pharmaceuticals.
The merger agreement and upcoming board refresh come after a strong run in Catalyst Pharmaceuticals’ stock, with a 90 day share price return of 20.16%, a year to...